Clinical trial
Randomised, Double-blind, Placebo-controlled, Clinical Study to Evaluate the Effect of Opicapone 50 mg on Parkinson's Disease Patients With End-of-dose Motor Fluctuations and Associated Pain.
NCT04986982 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomised, Double-blind, Placebo-controlled, Clinical Study to Evaluate the Effect of Opicapone 50 mg on Parkinson's Disease Patients With End-of-dose Motor Fluctuations and Associated Pain.
- Lead sponsor
- Bial - Portela C S.A.
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 25, 2021
- Completion date
- February 16, 2024
- Enrollment
- 144 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.